Table 2:

Crude and adjusted hazard ratios for the regional effect of sex and current CD4 cell count on the risk of developing NHL in adults who started ART.

	South Africa	Latin America	North America	Europe
	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)
Sex
Men	1.00	1.00	1.00	1.00
Women (crude)	1.00 (0.60 – 1.69)	0.23 (0.08 – 0.64)	0.52 (0.36 – 0.75)	0.54 (0.47 – 0.63)
Women (adjusted*)	1.13 (0.67 – 1.91)	0.24 (0.09 – 0.67)	0.52 (0.36 – 0.76)	0.59 (0.51 – 0.69)
Current CD4 cell count
Per 100 cells/μl increase (crude)	0.91 (0.77 – 1.07)	0.66 (0.54 – 0.80)	0.66 (0.61 – 0.71)	0.71 (0.69 – 0.73)
Per 100 cells/μl increase (adjusted**)	0.92 (0.78 – 1.08)	0.66 (0.55 – 0.80)	0.65 (0.60 – 0.71)	0.72 (0.69 – 0.74)

^*Adjusted for age at ART start, calendar year of ART start, first-line ART regimen, current CD4 cell count and its interaction with region (model 1).

^**Adjusted for age at ART start, calendar year of ART start, first-line ART regimen, sex and its interaction with region (model 1).

ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; NHL, non-Hodgkin lymphoma.